Functionally, dabrafenib led to a growth arrest in the BRAF‐ and RAS‐mutant melanoma cell lines, with a G1‐phase cell cycle arrest noted (Fig. 1E and 1F) (~ 10% in WM1366 cells). Here, BRAF is linked to melanoma.